Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 106Pancreatic Neoplasms 31Esophageal Neoplasms 17Esophageal Squamous Cell Carcinoma 11Biliary Tract Neoplasms 11Colorectal Neoplasms 10Cholangiocarcinoma 6Neoplasm Metastasis 5Nasopharyngeal Carcinoma 5Adenocarcinoma 5Recurrence 4Head and Neck Neoplasms 4Gastrointestinal Neoplasms 4Colonic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Rectal Neoplasms 3Advanced Pancreatic Cancer 3Advanced Gastric Cancer 3Stage IV Gastric Cancer With Metastasis 2Neoplasms 2NSCLC 2Locally Advanced Gastric Cancer 2Gastric Cancer Peritoneal Metastases 2Gastric Adenocarcinoma 2Gallbladder Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2mCRC 1Surgically-Created Resection Cavity 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

irinotecan sucrosofate 1apatinib 1Temozolomide 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Efficacy and Safety × S 1 (combination) × Clear all
NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
120 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡